Back to All

Director’s Shareholding - PCA Dealing

8 June, 2020

Diaceutics PLC (AIM: DXRX), the diagnostic commercialisation company, announces that Delia Keeling, wife of Peter Keeling, Chief Executive of Diaceutics, has transferred a total of 24,000 ordinary shares in the Company held by her to certain members of her family for nil consideration. The transfers were effected on 21 April 2020. The following additional information is disclosed in accordance with article 19(3) of the Market Abuse Regulation.

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1Details of the person discharging managerial responsibilities/person closely associated
a.NameDelia Keeling
2Reason for notification
a.Position/StatusWife of Peter Keeling, Chief Executive Officer of Diaceutics plc
b.Initial notification/ AmendmentInitial
3Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.NameDiaceutics plc
b.LEI213800VEWQBB39ZB8J81
4Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.Description of the financial instrument, type of instrument Identification CodeOrdinary shares of 0.2p each   ISIN: GB00BJQTGV64
b.Nature of the transactionTransfer of shares to certain family members for nil consideration. The transfer comprised 1,000 shares each transferred to 24 individuals, all for nil consideration.
c.Price(s) and volume(s)Price(s) Nil Volume(s) 24,000
d.Date of the transaction21 April 2020
e.Place of the transactionOutside a trading venue


About Diaceutics

At Diaceutics we believe that every patient should get the precision medicine they deserve. We are a data analytics and end-to-end services provider enabled by DXRX - the world’s first Network solution for the development and commercialization of precision medicine diagnostics. 

Diaceutics has worked on every precision medicine brought to market and provides services to 36 of the world’s leading pharmaceutical companies. We have built the world’s largest repository of diagnostic testing data with a growing network of 2500 labs in 51 countries.